Product Description
Mechanisms of Action: nAChR Binder
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Inhalant
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: National Institute on Drug Abuse (NIDA)
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Chronic Pain|Acute Pain
Phase 2: Tobacco Use Disorder
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PRE_Smoking | N/A |
Completed |
Pregnancy Outcomes|Hypertension, Pregnancy-Induced|Pre-Eclampsia |
2022-09-30 |
|
| NCT04274673 | P4 |
Unknown status |
Chronic Pain|Acute Pain |
2020-05-13 |
|
| CANICE | N/A |
Unknown status |
Tobacco Use Disorder|Carcinogenesis |
2017-11-01 |
|
| NCT03062709 | N/A |
Completed |
Smoking Cessation|Pneumonia|Bronchopulmonary Dysplasia|Asthma|Tobacco Use Disorder|Bronchiolitis |
2017-03-30 |
|
| SCUSF 1201 | P2 |
Withdrawn |
Tobacco Use Disorder |
2016-06-01 |
|
| R01HL066307 | N/A |
Completed |
Asthma |
2008-01-01 |
|
| ENtiCe | N/A |
Not yet recruiting |
Tobacco Use Disorder|Pregnancy Outcomes |
None |
|
| NIDA-09259-13 | P2 |
Completed |
Tobacco Use Disorder |
None |
|
| NIDA-09259-5 | P2 |
Completed |
Tobacco Use Disorder |
None |
|
| NIDA-09259-1 | P2 |
Completed |
Tobacco Use Disorder |
None |